Loading results…
Stock research, two ways
Who is buying this company from the inside, and is it a good business at a fair price. Two independent tools, one documented method each. Use either on its own — most companies worth researching have no insider buying at all.
Then $9.99/month. Cancel any time.
No card to start.
Officers and directors buying their own stock on the open market, minutes after they file.
Most of it means nothing, and the work is in the rejections: routine buyers, fund rebalancing, scheduled plan trades, 401k-sized contributions. What survives is measured against that company's own 24-month baseline.
Every US-listed operating company, scored on growth, financial strength and price.
Independent of the above — a company needs no insider filing to be worth researching. Three tests, all three passing is the sweet spot, and each number is shown with the threshold it had to clear.
1,772,554
filings held
Forms 3, 4 and 5 since 2018, polled every ten minutes
268,099
open-market buys
Code P only — grants, option exercises and tax withholding are not buying
258
clusters worth a look
Out of 452 in the last 30 days. The rest were filtered out
The rejections, not just the hits
Fund activity, 401k-sized contributions, same-day option exercise-and-sell, 10b5-1 plan trades, routine monthly buyers. Each one shown with the reason, never silently dropped.
Conviction as a percentage, not a headline
A $2m buy against 10.7m shares already held is a 0.5% add. A $158k buy taking a holding from 35k to 40k is real. The tool ranks on the second kind.
Is this unusual for this company?
Every cluster measured against that company’s own 24-month baseline, on a chart that draws the typical month as the line the spike has to clear.
Am I already late?
Price move since the first purchase in the cluster, on every row — because a stock that has already run is the case to skip.
Alerts when a cluster forms
Telegram or email, fired when a new filing joins a cluster — not every ten minutes for a month because it still qualifies.
A valuation read on any stock
PEG on the trailing P/E, against the growth analysts expect — with the P/E, the sales growth, the debt and the cash position beside it, and the threshold each one had to clear. For companies with no earnings to divide by, where the price sits against its industry on sales.
What the price is asking for
The growth a company would have to deliver to justify what it costs, next to what analysts actually expect — and the rate at which it would start to look expensive.
Every check written down
What gets thrown out, what gets flagged, and the reason for each — on the methodology page, in full. A filter you cannot see is one you cannot disagree with.
It is not a picks service and it does not forecast prices. A typical week surfaces a handful of insider clusters worth real work and often none worth acting on — that is the honest expected outcome of that method, not a fault in the tool. The valuation side is a starting point and not a verdict: it says what the numbers say, using thresholds borrowed from a published method, and roughly half the market is left explicitly unclassified because the ratios cannot reach it. What you are paying for is the collection, decoding and filtering that would otherwise cost hours by hand. The judgement stays yours. Nothing here is investment advice.
$9.99 / month
Free for 7 days. No card up front, cancel in one click.
Insider filings are public disclosures and reading them is entirely legal — the filings exist so that anyone can. How it works.